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Cellular microvesicles and nanovesicles (exosomes) are involved in many disease processes and have major potential as biomarkers.
However, developments in this area are constrained by limitations in the technology available for their measurement. Here we report on the
use of fluorescence nanoparticle tracking analysis (NTA) to rapidly size and phenotype cellular vesicles. In this system vesicles are visualized
by light scattering using a light microscope. A video is taken, and the NTA software tracks the brownian motion of individual vesicles and
calculates their size and total concentration. Using human placental vesicles and plasma, we have demonstrated that NTA can measure
cellular vesicles as small as ∼50 nm and is far more sensitive than conventional flow cytometry (lower limit ∼300 nm). By combining NTA
with fluorescence measurement we have demonstrated that vesicles can be labeled with specific antibody-conjugated quantum dots, allowing
their phenotype to be determined.
From the Clinical Editor: The authors of this study utilized fluorescence nanoparticle tracking analysis (NTA) to rapidly size and phenotype
cellular vesicles, demonstrating that NTA is far more sensitive than conventional flow cytometry.
© 2011 Elsevier Inc.
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Open access under CC BY license.Many cells shed small vesicles in a regulated way; such
vesicles have a key role in intercellular communication. In
general there are three main types of vesicles: apoptotic bodies
(500 nm–3 μm in diameter)1 released by cells undergoing
apoptosis, microvesicles (100 nm–1 μm), which directly bud
from the plasma membrane,2 and nanovesicles (30 nm–100 nm),
which include exosomes released via exocytosis from multi-
vesicular bodies of the endosome.3 All are involved in cell
signaling. The properties of cellular vesicles have been reviewed
extensively elsewhere,3-5 Briefly, (i) they carry diverse mem-
brane and cytosolic proteins as well as messenger and
microRNAs; (ii) they can affect the physiology of their target
cells in various ways, from inducing intracellular signaling
following binding to receptors, to conferring new properties afterlular vesicles using Nanoparticle Tracking Analysis. Nanomedicine: NBM
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fusion or endocytosis3-5; (iii) they participate in physiological
processes including hemostasis and thrombosis, inflammation,
immune interactions, and angiogenesis4,6; and (iv) circulating
levels are elevated in various disorders, including atherosclerosis
and coronary artery disease, pre-eclampsia, hematological and
inflammatory diseases, diabetes, and cancer.4 They may
therefore be useful as prognostic and diagnostic biomarkers for
early detection of a wide variety of diseases and have a potential
role in monitoring treatment.
Relevant research is constrained by the limitations of current
methods of measurement.7 Electron microscopy demonstrates
the presence of microvesicles and exosomes in ultracentrifuge
pellets of biological fluids (e.g., cell culture medium, plasma,
or urine) but either is not quantitative and requires extensive
sample preparation. The composition of pelleted material can
be determined by western blotting, but this gives no
information on the number of particles or their sizes.
Enzyme-linked immunosorbent assays do not capture all the
vesicles present, cannot discriminate between microvesicles and
exosomes, and also detect soluble antigens. Conventional flow
cytometry, using analogue or first-generation digital instru-
ments, is unable to detect vesicles of b300 nm (which excludes
exosomes).8 More recently atomic force microscopy has been
successfully used to determine the size distribution and number
of CD41+ vesicles in plasma, but this technique is highly labor
intensive.9 Dynamic light scattering (DLS), which determines
size by light scattered from particles under brownian motion,
can measure biological vesicles in suspension. A major
disadvantage is that it cannot resolve mixtures of microvesicles
and exosomes, because it is biased toward the detection of
larger particles.10
Here we describe nanoparticle tracking analysis (NTA), a new
method for direct, real-time visualization and analysis of
nanoparticles in liquids that overcomes many of the problems
associated with the above methods.11 NTA relates the rate of
brownian motion to particle size. In this system vesicles are
visualized by light scattering using a light microscope. A video is
taken, and the NTA software tracks the brownian motion of
individual vesicles and calculates their size and total concentration.
The purpose of this study was (i) to evaluate the potential of
NTA for measuring the size and concentration of microvesicles
and nanovesicles in biological samples and (ii) to demonstrate,
for the first time, how it can be developed to allow the vesicles to
be phenotyped using fluorescent antibodies. As mentioned
above, cellular microvesicles and nanovesicles can be found in
the circulation. However, the vesicles recovered from plasma are
derived from many different cell types including platelets,
endothelial cells, leukocytes, and red cells, which complicates
their analysis. We have therefore initially used vesicles derived
from the human placenta as a simple model for developing the
techniques described here. The placenta releases microvesicles
and nanovesicles into the maternal blood during pregnancy as
part of the normal turnover of the placental surface.12 Large
amounts of highly purified vesicles can be prepared, after
delivery, by perfusing the maternal surface of the placenta with
buffer, which mimics the maternal blood flow.13 The vesicles are
then recovered by ultracentrifugation for analysis. We have thendemonstrated that NTA can be used to analyze total cellular
vesicles in a complex biological fluid, human plasma, using a
fluorescent quantum dot-labeled cell tracker peptide.Methods
Preparation of placental vesicles
This study was approved by the Mid and South Bucking-
hamshire Research Ethics Committee. Placental vesicles were
prepared using a dual placental perfusion system.13 Placentas
were obtained from healthy pregnant women with informed
consent at caesarean section, without labor, and were processed
immediately. An individual lobule was isolated and the fetal
circulation perfused with 0.1-μm filtered modified M-199
tissue culture medium (medium 199 with l-glutamine and
Earle's salts, containing 0.8% dextran 20, 0.5% bovine serum
albumin, 5000 U/L sodium heparin, and 2.75 g/L sodium
bicarbonate, pH 7.4) containing a bolus of 100,000 IU
streptokinase to promote clot removal, at a rate of 5 mL/min.
The whole placenta was turned upside down and laid inside a
Perspex water jacket maintained at 37°C. Maternal perfusion
medium (0.1 μm filtered M-199 with l-glutamine and Earle's
salts, containing 0.5% bovine serum albumin, 5000 U/L
sodium heparin, and 2.75 g/L sodium bicarbonate, pH 7.4)
established the maternal circulation through eight 1.7-mm fetal
feeding tubes at a controlled rate of 20 mL/min. Perfusion
media were warmed in a 37°C water bath, and the maternal
perfusion medium was oxygenated with 95% O2, 5% CO2. The
lobule was perfused for 20 minutes to equilibrate the system,
after which the maternal circuit containing 600 mL of perfusion
medium was closed. The volume of fetal effluent was measured
every 2 minutes and the oxygen concentration of the maternal-
side perfusate monitored continuously to ensure stability.
Pressure monitors were used on both the maternal and fetal
sides of the placenta to ensure no significant deviations from
baseline occurred during the experimental period. After 3 hours
the maternal perfusate was centrifuged in a Beckman J6-M
centrifuge (Beckman Coulter, High Wycombe, United King-
dom) at 600 g for 10 minutes at 4°C. The remaining
supernatant was centrifuged at 150,000 g for 1 hour at 4°C
in a Beckman L8-80M ultracentrifuge (Beckman Coulter). The
resultant pellets were pooled and washed in phosphate buffered
saline (PBS) and then resuspended in PBS to a final total
protein concentration (BCA protein assay kit; Pierce, Thermo
Scientific, Rockford, Illinois) of 5 mg/mL and stored in
aliquots at −80°C until use.
Electron microscopy
For routine electron microscopy, formvar/carbon-coated grids
were floated on 50 μL drops of placental vesicle suspension,
washed in distilled water, and negatively stained with 1% methyl
tungstenate before examination in the electron microscope. For
immuno-electron microscopy, formvar/carbon-coated grids were
floated on 50 μL drops of placental vesicle suspension. The
vesicles were then labeled with the monoclonal antibody
NDOG2, specific for placental alkaline phosphatase, which is
Figure 1. NanoSight instrument configuration.
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PBS and then placed on a drop of primary antibody (NDOG2
1:50) in PBS for 20 minutes, washed in PBS, and placed on a
drop of secondary antibody (goat anti-mouse 1:25) conjugated to
10 nm colloidal gold for 20 minutes. The grids were then washed
in PBS, fixed with glutaraldehyde, washed in distilled water, and
negatively stained with 1% methyl tungstenate before examina-
tion in the electron microscope. Vesicle diameters were
measured manually from the electron micrographs by two
independent observers and the mean vesicle diameter calculated.
Nanoparticle tracking analysis
The system, the NanoSight LM10 (NanoSight Ltd., Ames-
bury, United Kingdom), uses a finely focused laser beam that is
introduced to the sample (a liquid containing a dilute suspension
of particles) through a glass prism (Figure 1). The beam refracts
at a low angle as it enters the sample, resulting in a thin beam of
laser light that illuminates particles through the sample. Particles
resident within the beam are visualized using a conventional
optical microscope, fitted with a video camera, aligned normally
to the beam axis, which collects light scattered from all particles
in the field of view. The sample chamber is ∼500 μm deep, but
the beam depth is around 20 μm at the point of analysis,
matching with the depth of focus of the imaging optics. A video
of typically 60 seconds duration is taken, with a frame rate of 30
frames per second, and particle movement is analyzed by NTA
software (NanoSight Ltd.). The NTA software is optimized to
first identify and then track each particle on a frame-by-frame
basis, and its brownian movement tracked and measured frame to
frame. The velocity of particle movement is used to calculate
particle size by applying the two-dimensional Stokes-Einstein
equation:
bx; yN2 =
KBTts
3pgdhwhere bx,yN2 is the mean squared displacement, KB is
Boltzmann's constant, T is the temperature of the solvent in
Kelvin, ts is the sampling time (i.e., 1/30 fpsec = 33 msec), η is
the viscosity, and dh is the hydrodynamic diameter.
A range of parameters can be adjusted both in video capture
(such as camera gain and shutter speed) and in analysis (such as
filter settings, background subtraction, minimum required track
length, and frame-to-frame search area), thus allowing the user to
optimize particle identification and tracking for a particular
sample. The range of sizes that can be analyzed by NTA depends
on the particle type—that is, whether it has a high (e.g., colloidal
gold) or a low refractive index (e.g., cellular vesicles). The lower
limit is a function of the signal-to-noise ratio of the image and is
thus strongly affected by the amount of light scattered. The
particles in consideration here (i.e., at the limit of detection of the
system) are in the Rayleigh scattering regime. In this regime the
amount of light scattering is given by:
rs =
2p5
3
d6
k4
n2−1
n2 + 2
 2
where d is the particle diameter, λ is the wavelength of light, and
n is the ratio of the particle refractive index to the solvent
refractive index. Generally speaking, cellular vesicles have a low
refractive index, and the smallest detectable size using the NTA
system is in the order of 50 nm. At ∼1 μm the brownian motion
of a particle becomes too limited to track accurately.
To demonstrate the ability of NTA to discriminate particles of
different sizes in a polydisperse sample, a 5:1 mixture of 100 nm
and 300 nm polystyrene beads (NIST beads; Thermo Scientific,
Fremont, California) was analyzed. To demonstrate how the
particle concentration can be estimated, 100 nm beads at a range
of concentrations between 2 × 108 and 20 × 108 particles per
milliliter were analyzed. Placental vesicles, stored in PBS at
−80°C, were thawed at room temperature (18−25°C) before
NTA analysis. Each sample was diluted in PBS over a range of
Figure 2. NTA measurement of particle size and concentration. (A)Mixture of 100 nm and 300 nm polystyrene beads (ratio 5:1) analyzed by NTA. (B) NTA
analysis of 100-nm beads at a range of concentrations from 2 × 108 to 20 × 108 per milliliter, mean ± SD of five replicates. The actual values for the concentration
of the beads are shown on the x-axis and those measured by NTA on the y-axis.
783R.A. Dragovic et al / Nanomedicine: Nanotechnology, Biology, and Medicine 7 (2011) 780–788concentrations between 2 × 108 and 8 × 108 vesicles per
milliliter. The samples were mixed before introduction into the
sample chamber and a video recording, typically 1 minute,
initiated. A combination of high shutter speed and gain followed
by manual focusing enables optimum visualization of a
maximum number of vesicles. To accurately track the vesicles
they must be visualized as single points of light. The NTA
software is unable to effectively track very large vesicles or those
with confounding Newton rings. In this case the shutter speed
and gain are reduced accordingly (see Supplementary Videos S1-
S3, which can be found in the online version of this article). For
highly polydisperse samples, multiple analyses at a range of
settings may be necessary. The samples were advanced between
each recording to perform replicate measurements. NTA post-
acquistion settings were optimized and kept constant between
samples, and each video was then analyzed to give the mean,
mode, and median vesicle size together with an estimate of the
concentration. An Excel spreadsheet (Microsoft Corp., Red-
mond, Washington) was also automatically generated, showing
the concentration at each vesicle size.
Immunofluorescence labeling with NDOG2 antibody
conjugated to quantum dots
Quantum dots were conjugated to NDOG2 antibody with a
Qdot 605 Antibody Conjugation Kit (Invitrogen, Paisley, United
Kingdom) coated with polyethylene glycol amine (molecular
weight 2000) according to the manufacturer's instructions.
Briefly, quantum dots were activated with the cross-linker 4-
(maleimidomethyl)-1-cyclohexanecarboxylic acid N-hydroxy-
succinimide ester (SMCC), yielding a maleimide-nanocrystal
surface. Excess SMCC was removed by size exclusion
chromatography. The antibody was then reduced by dithiothrei-
tol to expose free sulfhydryl groups, and excess dithiothreitol
was removed by size exclusion chromatography. The activatedquantum dots were covalently coupled with reduced antibody
and the reaction quenched with mercaptoethanol. Conjugates
were concentrated by ultrafiltration and purified by size
exclusion chromatography. Mouse immunoglobulin G was
labeled in the same way for use as the isotype control. Placental
vesicle suspension (see above) was diluted 1:100 and NDOG2-
conjugated quantum dots were added to give a final quantum dot
concentration of 10 nM. The molar ratio of antibody to quantum
dots was 3.5:1. After a 15 minute incubation at room
temperature, the labeled vesicles were diluted in PBS for
analysis by NTA.
Flow cytometry
Placental vesicles were analyzed using a Becton Dickinson
LSRII flow cytometer (Becton Dickinson, Oxford, United
Kingdom) equipped with a 405 nm (violet) and 488 nm
(blue) laser. A vesicle gate was determined using calibration
microspheres of various sizes (200 nm, 290 nm, 390 nm, 590
nm; Duke Scientific Corporation, Palo Alto, California) and 1
μm Fluoresbrite Plain YG beads (Polysciences Inc, Warring-
ton, Pennsylvania). Using a side-scatter (SSC) threshold of
200 arbitrary units the lower sensitivity of the instrument was
established and the SSC and forward scatter (FSC) voltages
were set. There is overlap in the 200 nm bead population and
the instrument noise (determined by running PBS filtered
through a 100 nm filter). Therefore, a gate was set to include
vesicles of 300 nm-1 μm in diameter. Vesicles were
enumerated by running Becton Dickinson TruCount Tubes
(three tubes per experiment) to establish the flow rate of the
system. All samples were run on the “LO” setting with a flow
rate of 12 μL per minute. Placental vesicles were diluted 1:50
in PBS and incubated with 10 μL of FcR receptor block at
4°C for 10 minutes. They were then incubated with NDOG2-
Qdot605 or IgG1-Qdot605 at 10 μg/mL and incubated for 15
Figure 3. Comparison of NTA, electron microscopy (EM), and flow cytometry analysis of placental vesicles. (A) Electron micrograph of placental vesicle
ultracentrifuge pellet. Scale bars, 200 nm. (B) Screen shot of video from NanoSight LM10 showing optimal light scatter from placental vesicles. (C) Vesicle
size determined by direct measurement from electron micrographs (blue bars) and NTA (red line). (D) Size resolution of marker beads by forward (FSC) and
side scatter (SSC) in flow cytometry. Instrument noise was defined by running 100-nm-filtered PBS. (E) Placental vesicle FSC and SSC by flow cytometry.
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mL with PBS and analyzed by flow cytometry.
Fluorescence NTA
The NanoSight NS500 instrument (NanoSight Ltd.) is a
development of the NanoSight LM10 that allows the detection
of microvesicles and nanovesicles labeled with stable fluor-
ophores. It uses a 405 nm (violet) laser diode to excite suitable
fluorophores whose fluorescence can then be determined using
a matched 430 nm long-pass filter. Measurements are made in
fluorescence mode with the long-pass filter in place so that
only fluorescently emitted light is measured. The fluorescent
particles are individually tracked in real time, from which
labeled particle size and concentration can be determined.
Under light scatter mode, the total number of particles can be
measured and subsequently compared to the concentration of
labeled particles. The calibration beads used were Nanosphere
Size Standards 200 nm [1.7% coefficient of variation (CV);
Thermo Scientific] and Fluoresbrite Plain YG 100 nm
Microspheres (5.8% CV) (Polysciences Inc.).
Labeling of plasma cellular vesicles with fluorescent
QTracker dye
Platelet-poor plasma was prepared from blood collected
into 0.106 mM trisodium citrate, by double centrifugation at2500 g for 15 minutes. Cellular vesicles were either labeled
directly in the plasma or after ultracentifugation of platelet-
poor plasma at 100,000 g for 1 hour at 4°C. Vesicles were
labeled using the QTracker cell labelling kit (Invitrogen,
Carlsbad, California), which uses a targeting peptide to deliver
QDot nanocrystals across the plasma membrane into the
cytoplasm.15 Briefly, 2 μL of a 0.625 nM solution of QTracker
quantum dots were added to 200 μL of plasma or plasma
vesicle pellet resuspended in PBS and incubated at 37°C for 1
hour. NTA analysis was performed using the NanoSight
NS500 instrument as described above.Results
NTA measurement of particle size and concentration
Figure 2, A shows that NTA successfully addresses one of
the key problems with DLS (i.e., polydispersity), in that it can
resolve and accurately measure different-size particles (here
100 nm and 300 nm polystyrene beads) simultaneously within
the same solution. Although the distributions partly overlap,
the two peaks of each bead subtype at 100 nm and 300 nm
peaks are clearly discriminated. This is an essential prerequi-
site for analyzing cellular microvesicles and nanovesicles in
biological fluids. The overlap of the peaks in Figure 2, A is
Figure 4. Fluorescence NTA analysis of placental vesicles. (A) Mixture of fluorescent 100 nm and nonfluorescent 200 nm beads analyzed on the NanoSight
NS500 using light scatter from the 405 nm violet laser (blue line) and the same bead mixture analyzed for fluorescence only using a 430 nm filter (red line). (B)
Placental vesicles labeled with mouse IgG1 isotype control antibody conjugated to quantum dots and analyzed by flow cytometry. (C) Placental vesicles labeled
with antibody NDOG2 specific to placental vesicles conjugated to quantum dots and analyzed by flow cytometry. (D) Immunogold labeling of placental vesicles
with NDOG2 antibody. (E) Placental vesicles labeled with antibody NDOG2 conjugated to quantum dots and analyzed on the NanoSight NS500 in light scatter
(blue line) and fluorescence (red line) modes. The green line shows placental vesicles labeled with the mouse IgG1 quantum dot isotype control antibody
analyzed in fluorescence mode.
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(brownian motion) by sampling over a finite time period (the
time for which each particle can be tracked). For analysis of
beads where the particle size distribution is well defined, the
NTA software can correct for this and produce tighter peaks.
However, for analyzing cellular vesicles where we cannot
make assumptions about the size distribution, we chose not to
use this correction, resulting in the apparent poorer resolution
seen here.
NTA also allows the particle concentration to be estimated
directly, with good linearity being seen between the actual
concentration and that measured by NTA in the range of 1 × 108-
8 × 108 beads per milliliter for monodisperse 100 nm beads
(Figure 2, B). Concentration measurement is less precise in
polydisperse samples. This is due to the need to use instrument
settings (camera shutter speed and gain) that are optimal for
smaller (e.g., 100 nm) particles to ensure that they are included in
the analysis. However, this leads to an overestimate of the
concentration of the larger particles (e.g., 300 nm), because at
these settings they may scatter multiple points of light, which are
interpreted by the software as individual particles (see Supple-
mentary Video S2).Comparison of NTA, electron microscopy, and flow cytometry
analysis of placental vesicles
The size distribution of placental vesicles was determined by
measuring their diameters directly from electron micrographs of
ultracentrifuge pellets. This showed a polydisperse sample with
vesicles ranging in size from 20 nm to 600 nm with a peak size
between 100 and 140 nm (Figure 3, A). Figure 3, B is a
screenshot of the same sample analysed on the NanoSight LM10
showing a range of vesicle sizes. NTA gave a similar vesicle size
distribution from 40 to 600 nm with a peak around 250 nm
(Figure 3, C). The peak of smaller material (20−60 nm) seen by
electron microscopy but not by NTA is partly due to the lower
sensitivity of the LM10 instrument in this size range, but
shrinkage artifacts during fixation for electron microscopy can
also lead to undersizing of the vesicles.16,17
We then demonstrated that NTA can measure vesicles that
cannot be detected by flow cytometry. Figure 3, D shows a
series of beads of standard sizes, analyzed by flow cytometry
on a FSC (size) versus SSC (granularity) plot. On our
instrument (Becton Dickinson LSRII), FSC can resolve beads
of 1 μm from 590 nm diameter, but nothing smaller. By adding
Figure 5. Fluorescence analysis of cellular vesicles in plasma. (A) Platelet-free plasma labeled directly with the QTracker cell-labeling reagent coupled to
quantum dots and analyzed on the NanoSight NS500 in light scatter (blue line) and fluorescence (red line) modes. (B) Ultracentrifuge pellet of the same plasma
sample labeled with QTracker and analyzed on the NanoSight NS500 in light scatter (blue line) and fluorescence (red line) modes.
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in the same region as instrument “noise.” On this basis, a 300
nm cutoff is a more realistic limit for practical use. The
placental vesicle preparation was then analyzed on these settings
by flow cytometry (Figure 3, E). The majority (N90%) of the
vesicles were below 1 μm in diameter, with the main population
at around 300-400 nm, cut off to the 300 nm detection limit. The
vesicle count was 1.6 × 109 per milliliter. When the same sample
was analyzed by NTA,∼70% of the vesicles were b300 nm and the
vesicle count was 3.7 × 1011 per milliliter. These results
demonstrate that NTA can measure the size and estimate the
concentration of biological microvesicles and nanovesicles as small
as ∼50 nm, with a sensitivity much greater than flow cytometry.
Fluorescence NTA of placental vesicles
A limitation of conventional NTA is that although it can
accurately measure vesicle size and concentration, it cannot
phenotype vesicles or determine their cell of origin in the way
that flow cytometry can. The NanoSight instrument has therefore
been developed to incorporate a 405-nm blue-violet laser and
more sensitive camera to detect fluorescent particles (Nano-
Sight NS500). Fluorophores (quantum dots) attached to
antibodies or other biological probes are excited; by using a
430-nm long-pass fluorescence filter, only vesicles that are
fluorescently labeled are tracked.
To demonstrate the principle, we first analyzed a mixture of
100-nm fluorescent beads and 200 nm nonfluorescent beads.
Figure 4, A shows the results using NTA in light scatter mode
(blue line). Although the distributions partly overlap for the
reasons discussed above, the two peaks of each bead subtype
at 100-nm and 200 nm peaks are clearly discriminated.
However, with the fluorescence filter in place only the
fluorescent 100 nm beads are tracked (red line). The size
and concentration of 100-nm fluorescent beads, either in light
scatter or in fluorescence mode, gave very similar results. We
then conjugated quantum dots to a mouse monoclonal IgG1
antibody (NDOG2), which is specific for placental vesicles,14
and confirmed that the conjugation was successful by showingthat 93.5% of the vesicles detectable by flow cytometry had
become labeled with the antibody (Figure 4, C), compared to
the quantum dot-labeled IgG1 isotype control (Figure 4, B).
We confirmed that the NDOG2 antibody bound to placental
vesicles smaller than 300 nm by immunogold electron
microscopy (Figure 4, D). The same samples were then
analyzed on the NanoSight NS500 instrument, first on light
scatter and then in fluorescence mode. Figure 4, E shows the
NTA of light scatter and fluorescence (see Supplementary
Video S4) for vesicles labeled with NDOG2-quantum dots and
IgG-quantum dot control. The size distributions of the
NDOG2-labeled vesicles are similar, with peaks in the region
of 100 nm and 180 nm (range 50−600 nm) whether measured
in light scatter or fluorescence mode. The small differences
between the peak sizes in light scatter and fluorescence modes
were within the observed level of variability (CV 8%) for this
technique. The concentration of NDOG2-positive vesicles is
slightly lower than that detected by light scatter, possibly as a
result of the presence of vesicles from contaminating blood
cells in the preparation that will not label with the NDOG2
antibody. The IgG-quantum dot control shows that the
NDOG2 antibody labeling of the vesicles is specific (see
Supplementary Video S5).
Finally, we analyzed cellular vesicles in human plasma by
labeling them with a cell tracker peptide conjugated to quantum
dots. Figure 5, A shows NTA analysis of platelet-poor plasma
labeled with the cell tracker dye in light scatter (blue line) and
fluorescence (red line) modes using the NanoSight NS500
instrument. The vesicle size ranged from 50 nm to 300 nm with a
peak size around 80 nm. The total vesicle count was 1.49 × 1012
per milliliter, whereas the labeled vesicle count was 1.2 × 1010
per milliliter. This difference is probably due to the presence of
large numbers of lipid vesicles (chylomicrons and very-low-
density lipoproteins) in the plasma, which are of a similar size to
cellular vesicles18,19 and can be detected by light scatter, but do
not label with the cell tracker dye. This is supported by the
analysis of the vesicles in the plasma ultracentrifuge pellet
(Figure 5, B), showing very similar counts whether the vesicles
were analyzed in light scatter (blue line, 1.4 × 1010 per milliliter)
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lipid vesicles would not be pelleted by ultracentrifugation,
whereas most of the cellular vesicles are recovered.Discussion
Cellular microvesicles and nanovesicles are potential markers
of human disease. To use these vesicles in diagnostic tests, a
simple and rapid method of simultaneously determining their
size, concentration, and phenotype in biological fluids such as
plasma and urine is required. This cannot be achieved by existing
methods. Our results demonstrate the feasibility of using NTA
for this purpose. This technology, although relatively new, is
well established in other fields including the measurement of
engineered nanoparticles, carbon nanotubes, inks and pigments,
protein aggregates, and viral particles.11
We have shown that NTA can be used to determine the size
and concentration of cellular vesicles and in doing so offers
distinct advantages over other methods. NTA is more rapid than
electron microscopy and atomic force microscopy, allowing
more vesicles to be analyzed and, because the vesicles are
analyzed in suspension, they are not subject to shrinkage
artifacts due to fixation. Crucially, it can detect nanovesicles
much smaller than those that can be seen by conventional flow
cytometry (∼300 nm). Although the latest generation of digital
flow cytometers can detect beads as small as 100 nm and can
discriminate these from 300 nm beads in a mixture,20 how these
measurements relate to the minimum size of cellular vesicles
that can be resolved must be interpreted with caution. Cellular
vesicles have a lower refractive index compared to latex or
polystyrene beads, which could lead to an underestimation of
their size.20,21 In contrast, because NTA determines particle size
from brownian motion, it is independent of the refractive index
of the particle.11 Flow cytometry analysis of placental vesicles,
which are likely to be composed of a range of exosomes,
microvesicles, and apoptotic bodies,1 showed that more than
90% were smaller than 1 μm, with the bulk of the population
closer to the 300 nm cutoff. NTA analysis confirmed the
presence of larger vesicles of 500−600 nm, but these were
relatively rare compared to the major population below 300 nm.
Although NTA can analyze particles as large as 1 μm in
diameter (above this the brownian motion is too slow to
measure), the large number of small vesicles in these
preparations requires that the sample be diluted for analysis
The effect of this is that the number of large vesicles analyzed is
significantly reduced, which means their concentration will be
underestimated. Thus, studies of large vesicles (N500 nm) alone
(e.g., apoptotic bodies) may be better carried out by flow
cytometry than by NTA.
DLS can also detect nanovesicles, but it cannot accurately
resolve heterogeneous mixtures of vesicles.22 This is because a
single detection element collects light from all particles
simultaneously; meaning that the estimate of particle size and
size distribution is biased to a larger particle size. In contrast,
NTA simultaneously measures particle size and scattering
intensity on individual particles, thus allowing heterogeneous
particle mixtures to be resolved. Furthermore, the ability of NTAto see particles directly and individually allow the particle
concentration to be estimated from extrapolating the number of
particles seen at any given instant to a particle concentration per
unit volume through knowing the scattering volume. This
facility, which is unobtainable by conventional DLS methods, is
invaluable for studying particles in biological fluids, because it
allows the measurement of changes in the concentration of
particles of different sizes between normal and disease states.
Thus, the NanoSight instrument allows a quantitative estimation
of sample size, size distribution, and concentration.
The disadvantage of NTA in its original form was that it
was unable to determine the phenotype of the vesicles.
Biological fluids such as plasma and urine will inevitably
contain mixtures of vesicles derived from many different cell
types. It is therefore crucial to be able to determine the cellular
origin of the vesicles and, to understand their biological
function, the molecules that they express on their surface. Here
we have successfully adapted and developed this technology
by adding a fluorescence capability and demonstrated the
proof of principle by measuring placental vesicles labeled with
a specific antibody conjugated to quantum dots and cellular
vesicles in human plasma using a quantum dot-labeled
fluorescent cell tracker peptide. Labeling with the cell tracker
peptide clearly shows that a large proportion of the vesicles in
plasma are not derived from cells but are probably lipid
vesicles, because they were removed by ultracentrifugation and
the cellular vesicles pelleted. Experiments are now under way
to label plasma vesicles with a panel of antibodies to platelet,
erythrocyte, leukocyte, and endothelial cell markers to
determine their composition. In summary, NTA in effect
extends the power of flow cytometry downward by nearly one
order of magnitude in terms of particle size and opens up new
possibilities for research into microvesicles and nanovesicles.Appendix A. Supplementary data
Supplementary materials related to this article can be found
online at doi:10.1016/j.nano.2011.04.003.References
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